Data initiative accelerates access to vital genetic and clinical insights.
We’re excited to announce the launch of the Lung Cancer Genetics Study Database! This database will allow qualified researchers to access de-identified data from consenting study participants at no cost. Research proposals will undergo a rigorous review process, and patients will help shape future research by reviewing and providing feedback on proposed research projects. To learn more and start the data access application process, contact study manager Caitlin Nichols at caitlin@twphilanthropies.org. To learn more about the Lung Cancer Genetics Study, visit www.23andme.com/lung-cancer #WCLC25. View the 23andMe blog post for more details.
At the 2025 World Conference on Lung Cancer in Barcelona, the 23andMe Research Institute, in collaboration with Troper Wojcicki Philanthropies and the health data software company Lifebit, introduced an open source platform that could help fast-track research discoveries through a powerful new cancer data repository.
The announcement comes just a year after the start of the Lung Cancer Genetics Study, spearheaded by 23andMe and bringing together more than 20 lung cancer advocacy and science organizations to recruit 10,000 people diagnosed with lung cancer. Their goal is to develop new ways to identify those at highest risk for lung cancer early, while also finding possible new treatments for this deadly cancer.
